Table 3.
Pre-transplant characteristics of recipients with HIV.
| Demographics | Recipient 1 | Recipient 2 | Recipient 3 |
|---|---|---|---|
| Age at transplant | 47 years | 52 years | 48 years |
| Sex | Male | Male | Male |
| Race | Black | Black | White |
| Hispanic/Latino ethnicity | No | No | Yes |
| Pre-transplant evaluation criteria, regardless of HIV status | |||
| Comorbidities | Hypertension, diabetes | Hypertension, diabetes | Hypertension |
| Body mass index | 27.8 kg/m2 | 20.1 kg/m2 | 30.2 kg/m2 |
| CMV IgG | Positive | Positive | Positive |
| Pre-transplant evaluation criteria, specific to research protocol for recipients with HIV | |||
| Prior opportunistic infection | None | None | None |
| Absolute CD4 | 1017 cells/μL | 511 cells/μL | 1211 cells/μL |
| HIV viral load | <20 c/mL | <20 c/mL | <20 c/mL |
| ART | RAL TDF FTC | RAL DRVr ETR | DTG RPV |
CMV, cytomegalovirus; IgG, immunoglobulin G; ART, antiretroviral therapy; RAL, raltegravir; TDF, tenofovir disproxidil fumarate; FTC, emtricitabine; DRVr, ritonavir-boosted darunavir; ETR, etravirine; DTG, dolutegravir; RPV, rilpivirine.